Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months

NCT01323946 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01323946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01323946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2011
Completion date
November 2, 2012
Enrollment
113 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza